CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 87 enrolled
Drug / intervention
Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG) +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00943800
NCT00943800N/ACompleted
CompareCT.gov

Combined Haploidentical-Cord Blood Transplantation for Adults and Children

University of Chicago·interventional·Posted Jul 22, 2009·Updated Jan 27, 2021

In Brief

A clinical study evaluating Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG), Stem Cell Transplant, and 3 other interventions for Leukemia and 3 related conditions. Completed, enrolled 87 participants across 1 site.

Detailed Summary

The primary objective is to assess the rate of engraftment with combined haploidentical-cord blood transplantation. The secondary objective is to evaluate the incidence and severity of acute and chronic graft-versus-host disease (GVHD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 22, 2009
Enrollment StartOct 9, 2006
Primary CompletionSep 1, 2018
TodayJul 2, 2026
Enrollment to primary: 11.9 yearsPosted 16.9 years ago

Interventions

Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG)drug

Fludarabine is given through the vein daily for 5 days. Melphalan is given through the vein daily for 2 days. ATG is given every day in the vein for four days.

Stem Cell Transplantprocedure

Infusion of haploidentical donor, umbilical cord blood

Stem Cells Collectionsprocedure

Haploidentical cells will be T-cell depleted using the Miltenyi Clinimax device.

Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI)drug

Fludarabine is given through the vein daily for 5 days. Thiotepa is given through the vein daily for 2 days. ATG is given through the vein every other day for 4 days. TBI is given twice a day for 3 days.

Fludarabine, Busulfan, and ATGdrug

Fludarabine is given through the vein daily for 5 days. Busulfan is given through the vein daily for 4 days. ATG is given through the vein every other day for 4 days.